Efruxifermin

Efruxifermin is a long-acting Fc-FGF21 fusion protein now in three concurrent Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), the liver disease driven by fat accumulation, inflammation, and progressive scarring [1][2]. As of December 9, 2025, efruxifermin is owned by Novo Nordisk following the completed $5.2B acquisition of Akero Therapeutics: $54 per share in cash (~$4.7B) plus a $6 per share contingent value right (~$500M) that pays out only upon FDA approval of efruxifermin for compensated MASH cirrhosis [7][8]. Phase 2b SYMMETRY 96-week data in cirrhotic MASH showed 39 percent of efruxifermin 50 mg completers achieved cirrhosis reversal without worsening of MASH versus 15 percent for placebo (29 percent vs 12 percent in the intent-to-treat analysis), a signal that reset expectations even though the 36-week primary endpoint was missed [3][9]. Novo Nordisk now runs the Phase 3 program from inside a company with global GLP-1 commercial infrastructure and semaglutide (ESSENCE) MASH data in hand, which reshapes both the competitive landscape and the combination-therapy potential. First registrational histology readout from SYNCHRONY HISTOLOGY Cohort 1 is guided for the first half of 2027; the event-driven cirrhosis outcomes trial reads out substantially later. The CVR structure means former Akero shareholders and market watchers have a direct binary payout tied to the compensated-cirrhosis approval [7][8].

Novel biologic, first-in-class among Fc-FGF21 fusions in late-stage MASH development. Now a wholly-owned Novo Nordisk subsidiary as of December 9, 2025 following the completed $5.2B acquisition (announced October 9, 2025) [7][8]. Novo Nordisk is running three registrational Phase 3 studies inherited from Akero. SYNCHRONY HISTOLOGY (NCT06215716, n=1,650) enrolls non-cirrhotic F2 to F3 MASH patients with histologic endpoints [4]. SYNCHRONY OUTCOMES (NCT06528314, n=2,150) enrolls compensated cirrhotic MASH patients with a clinical-events primary endpoint, the harder and more commercially valuable indication [5]. SYNCHRONY REAL-WORLD (NCT06161571, n=700) is a non-invasively diagnosed cohort supporting exposure and safety data; the double-blind portion completed enrollment in January 2025 [6][10]. FDA had granted efruxifermin Breakthrough Therapy designation for pre-cirrhotic MASH and Fast Track for compensated cirrhosis prior to the acquisition. Top-line histology data from SYNCHRONY HISTOLOGY Cohort 1 is guided for the first half of 2027; the cirrhotic outcomes trial reads out substantially later given its event-driven design. Because Akero is no longer publicly reporting, standalone cash runway is no longer a meaningful concern: development is now funded from Novo Nordisk's cash and operating base, which is among the largest in global pharma. No approved indications yet, so no direct revenue from this program.

FGF21 is a hormone the liver secretes when it senses metabolic stress. It travels to fat tissue, brain, and other organs and instructs the body to burn fat, cut back on sugar production, and increase insulin sensitivity. In MASH, that metabolic switch is broken, fat accumulates inside liver cells, and chronic inflammation drives scarring. Efruxifermin is a synthetic version of FGF21 fused to the Fc region of an antibody, which lets it stay in the bloodstream for about a week instead of the roughly two hours native FGF21 lasts. That enables once-weekly subcutaneous dosing. Mechanistically it activates FGFR1c, FGFR2c, and FGFR3c receptors, but only in the presence of beta-Klotho, a co-receptor mostly expressed on liver, fat, and pancreas. That tissue-restricted signaling is what keeps FGF21 analogs from causing the generalized FGFR toxicity seen with FGFR inhibitors used in oncology. The mechanism has more validation than most MASH targets. Human genetics show FGF21 loss-of-function alleles increase liver fat. Prior clinical data with pegbelfermin (Bristol-Myers Squibb) produced mixed Phase 2b fibrosis data before discontinuation as part of a pipeline prioritization: FALCON 1 (F3 non-cirrhotic MASH) missed its primary endpoint due to lack of dose response (14 percent placebo vs 24 to 31 percent across pegbelfermin arms, p=0.134), and FALCON 2 (compensated cirrhotic MASH) also missed its primary fibrosis-improvement endpoint, though NAFLD activity score improvements were more frequent with active drug [11]. Efruxifermin's own Phase 2 studies (HARMONY, BALANCED, SYMMETRY) and pegozafermin's ENLIVEN Phase 2b showed reductions in liver fat, improvement in non-invasive fibrosis biomarkers, and glycemic benefits, providing convergent class-level support even after pegbelfermin fell out [2][3][8][12]. Recent network meta-analyses put efruxifermin at or near the top of ranked MASH agents on both fibrosis improvement and MASH resolution, with resmetirom close behind [1][2][8].

SYNCHRONY HISTOLOGY (NCT06215716) enrolls 1,650 patients with biopsy-confirmed F2 or F3 fibrosis, randomized to 50 mg efruxifermin, 28 mg efruxifermin, or placebo, dosed subcutaneously weekly. Cohort 1's primary endpoint is the FDA-accepted composite: resolution of MASH with no worsening of fibrosis, OR at least one-stage fibrosis improvement with no worsening of steatohepatitis, evaluated by central paired biopsy read [4]. This is the same endpoint framework resmetirom used for accelerated approval. SYNCHRONY OUTCOMES (NCT06528314) enrolls 2,150 patients with compensated MASH cirrhosis (F4), with a time-to-clinical-event primary endpoint covering progression to decompensation (loss of the liver's compensatory capacity, marked by events like ascites fluid accumulation, variceal bleeding, or hepatic encephalopathy), transplant, MELD progression (Model for End-Stage Liver Disease, a standardized severity score used for transplant prioritization), or death [5]. Event-driven cirrhosis trials are the definitive commercial pathway because that is where the deaths and hospital costs concentrate, and no competitor has convincing data in this population. SYNCHRONY REAL-WORLD (NCT06161571) is an active-not-recruiting non-invasive cohort primarily supporting exposure and safety data; the double-blind portion finished enrollment in January 2025 [6][10]. The main design concern is the one that killed obeticholic acid and selonsertib: MASH histology is noisy, inter-reader variability is high, and placebo response rates on the composite endpoint run 10 to 25 percent in modern trials. Akero's SYMMETRY 96-week data (published in NEJM) showed 39 percent of efruxifermin 50 mg completers achieved cirrhosis reversal without worsening of MASH versus 15 percent placebo, and 29 percent vs 12 percent in the ITT analysis, which is the empirical basis for the Phase 3 cirrhosis program despite the earlier 36-week primary endpoint miss [3][9]. The most mechanistically comparable competitor, pegozafermin (89bio, glycoPEGylated FGF21), posted positive 48-week ENLIVEN Phase 2b data (192 patients) and is now in the parallel Phase 3 ENLIGHTEN program: ENLIGHTEN-Fibrosis (~1,000 patients, F2/F3) and ENLIGHTEN-Cirrhosis [12][13]. Two FGF21-class Phase 3 programs reading out in roughly the same window (2027) means the commercial narrative may hinge on head-to-head placebo-adjusted separation, tolerability, and dosing frequency rather than mechanism differentiation.

Our model estimates a 27% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 54%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by strong earlier-phase results and more secondary endpoints than usual; it is held back by heavier-than-usual blinding and the sponsor's thin or weak approval record. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: the histologic composite endpoint requires visible fibrosis regression on paired liver biopsy, and inter-reader variability plus double-digit placebo response rates have sunk programs with strong biomarker signals but weak histology separation [3]. Selonsertib is the cautionary example. SYMMETRY missed its 36-week primary endpoint before the 96-week secondary analysis showed separation, a reminder that the Phase 3 histology endpoints could look worse before they look better. Safety risk: FGF21 analogs consistently show class-related GI effects (diarrhea, nausea) at active doses, tolerable but not trivial. Longer-term signals to watch are bone metabolism (FGF21 has been linked to bone loss in preclinical work), IGF-1 modulation, and injection-site reactions. Weekly subcutaneous injection is a compliance drag versus oral resmetirom, though Novo Nordisk's injection-experienced patient base from the GLP-1 franchise partially mitigates the burden. Execution risk: three concurrent Phase 3 trials in a biopsy-intensive indication remain expensive and operationally complex, but with Novo Nordisk backing, financing pressure has been removed as a variable. Competitive risk: resmetirom launched in March 2024 and generated meaningful revenue in year one with a growing prescriber base [1]. Any efruxifermin approval enters a market with an entrenched oral competitor. The differentiated pitch has to be cirrhosis (where resmetirom lacks label support) plus superior fibrosis regression in F2/F3. Pegozafermin poses direct mechanism-class competition on a similar Phase 3 timeline. GLP-1s and dual agonists could shift standard of care before either FGF21 approves. CVR risk (for former Akero shareholders): the $6 per share contingent value right pays only upon FDA approval of efruxifermin for compensated MASH cirrhosis, so if SYNCHRONY OUTCOMES misses, the $500M CVR bucket is worthless [7][8].

Worth watching, but no longer directly investable as a standalone equity: Akero is now inside Novo Nordisk. The remaining public-market exposure is (a) Novo Nordisk itself, where efruxifermin is one of many pipeline assets, and (b) the non-transferable CVR held by former Akero shareholders, which pays $6 per share only on FDA approval for compensated MASH cirrhosis [7][8]. The specific signal to check is SYNCHRONY HISTOLOGY Cohort 1, guided for the first half of 2027. If efruxifermin at 50 mg posts a 15-percentage-point or greater separation over placebo on the composite histologic endpoint, that clears the Rezdiffra bar and sets up an accelerated approval filing. If separation is under 10 points, the cirrhosis outcomes trial becomes the entire thesis (and the entire CVR). The SYNCHRONY OUTCOMES cirrhosis readout is further out but is the more valuable indication because compensated MASH cirrhosis has no approved therapy, high mortality, and payers will reimburse aggressively for anything that delays decompensation. Recent network meta-analyses rank efruxifermin and resmetirom as the two leading MASH agents, with efruxifermin edging on fibrosis endpoints and resmetirom winning on oral convenience [1][2][8]. The wild card is Novo Nordisk's ability to run combination or sequencing studies with semaglutide, which no independent Akero could have contemplated. Monitor FDA's evolving stance on non-invasive biomarkers (MRI-PDFF, FibroScan, NIS4), since regulatory acceptance of these endpoints could shorten the path to approval by removing paired biopsy requirements. Track pegozafermin's ENLIGHTEN Phase 3 readouts as the class-level tell.